1. Klaver CC, Wolfs RC, Vingerling JR. . Age-specific preva-lence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998; 116:653–8.
2. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visu-al loss in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996; 103:357–64.
3. The Korean Retina Society. Retina. 4th. Vol. 1. Seoul: Jin Printing and Communication;2015; 283–305.
4. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008; 33:111–31.
Article
5. Noma H, Funatsu H, Yamasaki M. . Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005; 140:256–61.
Article
6. Yoshimura T, Sonoda KH, Sugahara M. . Comprehensive anal-ysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009; 4:e8158.
Article
7. Fujikawa M, Sawada O, Miyake T. . Correlation between vas-cular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion. Clin Ophthalmol. 2013; 7:1497–501.
Article
8. Hoeh AE, Ach T, Schaal KB. . Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009; 247:1635–41.
Article
9. Prager F, Michels S, Kriechbaum K. . Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009; 93:452–6.
10. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for mac-ular edema secondary to branch retinal vein occlusion. Retina. 2011; 31:1856–62.
Article
11. Hikichi T, Higuchi M, Matsushita T. . Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2014; 98:195–9.
Article
12. Lee YS, Kim MS, Yu SY, Kwak HW. Two-year results of intra-vitreal bevacizumab injection in retinal vein occlusion. J Korean Ophthalmol Soc. 2011; 52:1039–47.
Article
13. Carmeliet P, Ruiz de Almodovar C. VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration. Cell Mol Life Sci. 2013; 70:1763–78.
Article
14. Brar VS, Sharma RK, Murthy RK, Chalam KV. Evaluation of dif-ferential toxicity of varying doses of bevacizumab on retinal gan-glion cells, retinal pigment epithelial cells, and vascular endothe-lial growth factor–enriched choroidal endothelial cells. J Ocul Pharmacol Ther. 2009; 25:507–11.
Article
15. Foxton RH, Finkelstein A, Vijay S. . VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013; 182:1379–90.
Article
16. Tan O, Chopra V, Lu AT. . Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009; 116:2305–14. e1-2.
Article
17. Kim NR, Kim JH, Lee J. . Determinants of perimacular inner retinal layer thickness in normal eyes measured by Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011; 52:3413–8.
Article
18. Wollstein G, Schuman JS, Price LL. . Optical coherence to-mography (OCT) macular and peripapillary retinal nerve fiber lay-er measurements and automated visual fields. Am J Ophthalmol. 2004; 138:218–25.
Article
19. Nakatani Y, Higashide T, Ohkubo S. . Evaluation of macular thickness and peripapillary retinal nerve fiber layer thickness for detection of early glaucoma using spectral domain optical coher-ence tomography. J Glaucoma. 2011; 20:252–9.
Article
20. Cho JW, Sung KR, Lee S. . Relationship between visual field sensitivity and macular ganglion cell complex thickness as meas-ured by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2010; 51:6401–7.
Article
21. Tan O, Chopra V, Lu AT. . Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009; 116:2305–14. e1-2.
Article
22. Takagishi M, Hirooka K, Baba T. . Comparison of retinal nerve fiber layer thickness measurements using time domain and spectral domain optical coherence tomography, and visual field sensitivity. J Glaucoma. 2011; 20:383–7.
Article
23. Park CH, Lee KI, Park HY. . Changes in the retinal nerve fiber layer after intravitreal injections of bevacizumab in glaucoma patients. J Korean Ophthalmol Soc. 2014; 55:693–701.
Article
24. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F. . Retinal nerve fiber layer thickness changes in patients with age-re-lated macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012; 53:6214–8.
Article
25. Kim MJ, Woo SJ, Park KH, Kim TW. Retinal nerve fiber layer thickness is decreased in the fellow eyes of patients with unilateral retinal vein occlusion. Ophthalmology. 2011; 118:706–10.
Article
26. Brar VS, Sharma RK, Murthy RK, Chalam KV. Bevacizumab neu-tralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis. 2010; 16:1848–53.
27. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF an-tibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007; 91:1230–3.
Article
28. Shin HJ, Shin KC, Chung H, Kim HC. Change of retinal nerve fi-ber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014; 55:2403–11.
Article
29. Williamson TH. Central retinal vein occlusion: what's the story? Br J Ophthalmol. 1997; 81:698–704.
30. Munk MR, Sacu S, Huf W. . Differential diagnosis of macular edema of different pathophysiologic origins by spectral domain optical coherence tomography. Retina. 2014; 34:2218–32.
Article